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Objectives: the aim of this study was to detail the current consensus amongst vascular surgeons in Great Britain and
Ireland regarding their investigation and management of patients with suspected or proven deep vein thrombosis (DVT).
Methods: the database of the Vascular Surgical Society of Great Britain and Ireland (VSS) was utilised to send coded
postal questionnaires to all consultant surgeon members.
Results: replies were received from 281 (65%) consultants. Duplex ultrasound is used alone to confirm DVT by 69%
of respondents. A thrombophilia screen is always performed by 14% of consultants, for patients with proven DVT, and
is more commonly requested by consultants based in a teaching hospital. The majority (57%) of consultants treat DVT
with unfractionated heparin (UFH) and warfarin, whereas only 38% utilise low molecular weight heparins (LMWH)
and warfarin. A management policy for DVT is reported to be in place by 59%, and a set policy for the specific
management of calf vein DVT by just 20%.
Conclusion: new diagnostic modalities and treatments have been developed for DVT that are more convenient and cost-
effective. Although clinical guidelines for the management of patients with DVT are beginning to emerge, there is still a
wide discrepancy in many areas of DVT management, and practice at variance with the current evidence base, amongst
vascular surgeons in the United Kingdom and Ireland.
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Introduction suspected, on account of the high diagnostic accuracy
usually achieved.3,4
The natural history of DVT is now better understoodPrompt diagnosis and appropriate treatment of deep
and in particular the significance of isolated calf veinvenous thrombosis (DVT) is necessary to reduce the
thrombosis is recognised. Numerous different primarylong-term morbidity associated with chronic venous
hypercoagulable states are documented and overall,hypertension and mortality from pulmonary em-
42–46% of patients with a lower extremity DVT canbolism. Modalities of investigation and treatment have
be characterised as thrombophilic on this basis.4 Thechanged repeatedly over the last 40 years. Prior to
adoption of thrombophilia testing has therefore be-1960 the diagnosis of DVT was largely a clinical one,
come more widespread. Additionally, over the lastalthough it is now recognised that the clinical signs
two decades there have been numerous randomisedare non-specific, inaccurate and frequently absent.1
controlled studies on the medical management of DVT,The use of accurate confirmatory tests is imperative.
including the optimal duration of anticoagulation andSince the widespread introduction of venography in
the efficacy of using low molecular weight heparinsthe 1960s many other investigative modalities have
(LMWH).5–10 This growing evidence base is directingbeen evaluated. These include amongst others, ple-
changes to practice. The aim of this study was tothysmography (strain-gauge, impedance, segmental
survey the policies of consultant vascular surgeons inair, and photo), radio-nuclide imaging, d-dimer tests
Great Britain and Ireland regarding their preferredand continuous wave Doppler ultrasound (duplex
investigation and management of patients with sus-ultrasound).2,3 Venous duplex imaging is now the in-
pected or proven DVT.vestigation of choice in most units where DVT is
Methods
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Table 1. Adaptation of DVT management questionnaire.
Leeds DVT Management Study
Return form in reply-paid envelope Instructions: Please clearly circle correct response or write alternative answer
where appropriate
1. What speciality are you in? Vascular/Gen’ Surgery+Vascular/Other
2. Where do you work? D.G.H./Teaching hospital
3. What age group do you belong to? 30–39/40–49/50–60/60+/Other
4. What is your routine investigation to exclude/ Ultrasound/Colour duplex/Venography/Plethysmography e.g. light reflection
confirm DVT?
5. Does your investigation specifically look for Yes/No/Don’t know
calf vein DVT?
6. Do you request a thrombophilia screen on Always/Never/Selective: Multiple DVTs
patients with DVT? +ve Family History
No precipitating cause
7. Which of these does your thrombophilia Protein C def
screen evaluate? Protein S def
Factor V Leiden
Antithrombin III def
Anti-cardiolipin Ab
Lupus anticoagulant
Other
8. In a case of proven proximal DVT (popliteal LMWH alone
or femoral), do you use: UFH alone
LMWH and then warfarin
UFH and then warfarin
Other
9. Following DVT associated with the following No risks/Correctable risks e.g. OCP/HRT/Bed rest/Un-correctable risks e.g.
circumstances, for how long would you usually protein C deficiency
anticoagulate with warfarin? (3, 6, 12 months or other)
10. You have a patient who clinically might have Calf veins clear/Calf veins partly clear or unsure/Calf vein thrombosis
a DVT. Colour duplex shows patent popliteal (reassure, aspirin, TED+mobilise, UFH, LMWH, Heparin+warfarin, rescan, other)
and femoral veins. How do you manage this
patient given the following information?
11. For your patient with a proven calf vein DVT HRT/O.C. Pill/Smoking
only and NO other risk factors, would you (if (permanently, temporarily, other)
relevant) advise to stop:
12. Does your hospital have a set policy for DVT Yes/No
management?
13. Does your hospital have a set policy for calf Yes/No
vein DVT management?
LMWH=low molecular weight heparin; UFH=unfractionated heparin.
with an interest in vascular surgery using a postal investigation for suspected DVT; thrombophilia
screening; preferred anticoagulant therapy; length ofquestionnaire (Table 1). Questionnaires were dis-
patched between June 1998 and January 1999. The treatment; the influence of specific risk factors on
patient management; existence of specific policies forresponses were treated anonymously though the ques-
tionnaires were coded. If no response was received DVT management.
after 4 weeks a subsequent questionnaire was dis-
patched and the process repeated up to three times.
Reply-paid envelopes were used for the return of data.
The questionnaire was designed to ensure simple and Results
unambiguous completion using categorical responses
to ensure a high reply rate. Four hundred and thirty-two consultant members of
the VSS were contacted. The response rate was 65%Consultants’ views were surveyed with respect to
the following main aspects relating to DVT: choice of (281). Two-thirds of respondents practised in the set-
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Table 2. Preferred investigation used to diagnose DVT, and the
use of a thrombophilia screen in patients with DVT, according to
practice in teaching hospitals (TH) or district general hospitals
(DGH).
Investigation for DVT TH (%) DGH (%) p-value∗
Duplex ultrasound 84 (87) 111 (60) <0.001
Duplex+Venography 5 (5) 28 (15) <0.05
Ultrasound (B-mode) 2 (2) 19 (10) <0.05
Venography 3 (3) 16 (9) ns
Ultrasound+Venography 3 (3) 6 (3)
Other 0 (0) 4 (2)
Thrombophilia screen requests
Always 21 (22) 18 (10) <0.05
Selective 74 (76) 155 (84)
Never 0 (0) 9 (5)
Unspecified 2 (2) 2 (1)
∗Chi-square test with Yates correction, 1 d.f.
ting of a district general hospital (DGH) and one-third
Fig. 1. The components of the thrombophilia screen usually re-
in a teaching hospital (TH). quested by respondents when assessment is required.
Table 3. Choice of anticoagulation used by respondents in theDiagnosis treatment of proven proximal DVT.
Treatment Number (%)Duplex ultrasound is the preferred routine in-
vestigation used to confirm/exclude DVT. It is used Heparin then warfarin 161 (57)
in isolation by 69% of respondents, and in combination LMWH then warfarin 106 (38)
Either dual regime 7 (3)with venography by 12%. B-mode ultrasound is used
Heparin alone 1 (0)by 8%, and venography by 7%. The remainder (4%) LMWH alone 2 (1)
use other combinations of ultrasound, venography
and plethysmography. The majority of respondents
(74%) report that calf vein DVT is specifically sought
during their routine investigation for DVT. Table 2
demonstrates that there is a statistically significant
difference in practice amongst consultants employed
in a TH compared to a DGH with respect to their
investigative modality for DVT and usage made of
thrombophilia screens.
The components of the thrombophilia screen in use
by respondents are shown in Figure 1. The components
of the thrombophilia screen that the majority (57%) of
consultants request comprise assays for protein C, S,
antithrombin III, factor V Leiden, and anti-cardiolipin
antibody. This complete screen is more commonly
performed by consultants practising in a TH, 93%,
compared to a DGH, 38%, (p<0.0001 Chi-square test,
1 d.f).
Fig. 2. Length of anticoagulation with warfarin following DVT
according to the presence or absence of risk factors. Correctable risks:
Treatment e.g. bed rest, use of oral contraceptive pill or hormone replacement
therapy; un-correctable risks: e.g. protein c deficiency.
Table 3 shows the preferred treatment of a proven
proximal DVT, and Figure 2 illustrates the length of The management of the patient with clinical signs
suggesting the possibility of DVT, but with duplextime anticoagulation is prescribed for differing levels
of risk of recurrent DVT. ultrasound showing patent femoral and popliteal
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Discussion
The limitations of a survey of this kind include an
inability to ask questions regarding all areas relating
to DVT management. In particular, several areas of
interest that we omitted for sake of brevity included
views on DVT prophylaxis, d-dimer assays, outpatient
treatment, thrombolysis, and vena cava filter place-
ment. However, we feel that a 65% response rate has
provided a representative view of many important
methodologies used in the management of DVT
amongst surgical members of the VSS.
In recent years the use of duplex ultrasound has
become widespread and is now regarded by many asFig. 3. Types of treatment prescribed for clinical suspicion of DVT,
when femoral and popliteal veins are patent on duplex ultrasound the standard modality for assessment of DVT.11–14 It
imaging, given the following three scenarios with respect to the calf offers several advantages over venography in theveins: clear; uncertain; or thrombosed.
assessment of suspected acute DVT: it is non-invasive,
quick to perform and interpret, no contrast agent is re-
quired, and it is highly sensitive and specific.3,4,11,13,15
Our survey shows that duplex ultrasound alone is the
preferred investigation for suspected DVT, although
it is used relatively less by consultants who practice in
a DGH. This may be a reflection of available resources,
particularly at nights and weekends.
Nearly a quarter of all respondents said their routine
investigation for DVT does not specifically assess for
calf vein thrombosis. There was a similar paucity in
respondents who said their department have a set
policy for the management of calf vein thrombosis.
This is perhaps because isolated thrombosis at this
site is still considered by some to be unusual or of no
clinical importance. However, recent studies dem-
Fig. 4. Advice given to patients (when relevant) to stop hormone onstrate that isolated calf vein thrombosis is common
replacement therapy (HRT), the oral contraceptive pill (OCP), or and represents up to one-third of all DVT16,17 andsmoking in the circumstance of proven calf vein DVT and no other
may be even higher than this in those patients withrisk factors.
asymptomatic DVT.18 Lohr et al.19 studied 192 patients
with isolated calf vein thrombosis with sequential
duplex ultrasound and demonstrated propagation ofveins, is not an uncommon scenario. Figure 3 illustrates
thrombus in 28% of cases. The short-term risk of pul-how respondents treat that situation given three dif-
monary embolism is certainly low, but not zero,20–23ferent degrees of certainty about the state of the calf
and in the long term a quarter of patients may beveins. Figure 4 shows the advice consultants give to
expected to have persisting symptoms and developpatients who are taking the oral contraceptive pill
valvular incompetence.20 The peroneal and posterior(OCP) or hormone replacement therapy (HRT), or to
tibial veins are involved in the majority of cases ofthose who smoke, when that patient has a confirmed
calf vein thrombosis, and in symptomatic patients,diagnosis of calf vein DVT.
duplex ultrasound remains the initial investigation ofOverall, 59% of consultants said their hospital has
choice.14,17,24 If the initial scan is negative a repeata set policy for DVT management, although just 20%
scan in 3–4 days should be requested, with ascendingsaid there is a set policy for the management of calf
venography in those who remain clinically suspiciousvein DVT.
in the presence of a normal duplex.25There is no statistically significant difference in any
Alternatively, a clinical scoring system can be used,treatment preferences, advice preferences, or whether
such as that suggested by Wells et al.,26 to categorisea DVT management policy exists, in relation to
whether respondents worked in a TH or DGH. patients with suspected DVT (below or above knee)
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into low, medium, and high risk prior to imaging. the variety of responses in our survey (Fig. 2). The
Duration of Anticoagulation (DURAC) Trial9 in 1995,Only 5% of patients in the low clinical category have
DVT. Therefore, if ultrasound examination is negative found a significant reduction in the risk of recurrent
thromboembolism when the duration of oral anti-in this group DVT can be safely excluded, as the
negative predictive value is 99%. In the moderate or coagulant therapy was extended from six weeks to six
months after a first episode of venous thrombo-high-risk clinical categories, a repeat ultrasound or
venogram is suggested after 7 to 10 days. A negative embolism. The risk of recurrent thromboembolism may
persist for many years31 and recent evidence from ad-dimer test in patients with symptoms of DVT but
at low clinical risk for DVT may reduce the need double blind randomised study, for treatment of patients
with their first episode of DVT, suggests that continuingfor duplex ultrasound assessment,27 although there is
insufficient evidence at present to justify changes to warfarin beyond 3 months significantly reduces the
risk of recurrent thrombosis.10 Patients with DVT andcurrent clinical practice.
Approximately 50% of patients with idiopathic DVT correctable or reversible risk factors have been shown
to have a lower risk of recurrence than those withwill be found to have an inherited thrombophilia
usually caused by either activated protein C resistance, idiopathic DVT or un-correctable risks.10,31,32 We would
recommend that for the majority of patients with theirprotein C, S, or anti-thrombin III deficiency.12 It has
been suggested that overall, up to 46% of patients first DVT, warfarin treatment should be given for 6
months (including the idiopathic DVT group) to elim-with a lower extremity DVT can be characterised as
thrombophilic.4 Over 90% of vascular surgeons in our inate the high risk of relatively early recurrences. This
may be reduced to 3 months in those patients withsurvey perform a thrombophilia screen routinely or
selectively. However, screens are less often complete isolated symptomatic calf vein thrombosis and a re-
versible or temporary risk factor. However, in patientsfrom DGH respondents and overall, 28% of re-
spondents indicate that their thrombophilia screen with recurrent DVT or un-correctable risks, (e.g. in-
herited thrombophilia) treatment should continue fordoes not assay for resistance to activated protein C
(factor V Leiden mutation). This may be because some longer than 6 months and possibly indefinitely de-
pending on the individual circumstances.9,30 In this latteraspects of the screen are only available in the larger
DGH or TH. The factor V Leiden mutation is ten times group, account must be taken of a variety of risk factors
and prolonged therapy re-evaluated periodically, as themore common than other inheritable defects.28,29 We
would recommend a complete thrombophilia screen efficiency during continuing treatment decreases while
the risk for major bleeding continues.33(to include activated protein C resistance) be per-
formed in those patients with recurrent thrombosis, The majority of respondents in our survey advise
patients to stop smoking after the diagnosis of calfidiopathic thrombosis, thrombosis in the young, or
with a positive family history of thrombosis. As re- vein DVT. Due to the design of our questionnaire, it
was not possible to differentiate whether this advicesistance to activated protein C is the most important
hereditary cause of venous thrombosis, with a high was specifically related to a view that smoking rep-
resents an independent risk of future DVT, or basedprevalence, an argument could be made for the testing
of all thrombosis patients for this abnormality. simply on good practice. There have been few studies
to explore the relationship between smoking and riskAnticoagulation therapy is begun after a diagnosis
of DVT has been made, with either UFH or LMWH of venous thrombo-embolic events. In one small study
by Krupski et al.,34 thrombus progression followingfollowed by warfarin. A 5 day initial course of UFH
then warfarin, is just as effective as longer duration DVT was correlated with smoking. In another study
smoking was identified as a risk factor for pulmonaryof heparin then warfarin.5 A number of meta-analyses
have compared the safety and efficacy of LMWH with embolus in women.35
With respect to advice to discontinue the OCP afterUFH in the treatment of patients with acute venous
thrombosis.6–8 All showed LMWH was safer and more DVT, 80% of respondents advise patients to permanently
stop. More variable advice is given to those on HRT,effective than UFH. However, vascular surgeons in
our survey still favour the use of UFH and warfarin with 46% advising patients to permanently stop, and
40% to temporarily stop. This reflects the well recognisedover LMWH and warfarin. This may simply be due
to slow adoption of the LMWH regime in various pro-coagulant effects of oestrogen-containing oral con-
traceptives.36,37 Although the potency of oestrogen inhospitals and we suspect the proportion would be
different if this study were repeated. HRT is a quarter that in the OCP it is also recognised
to increase the risk of DVT.38 This may explain the moreThe period of anticoagulation with warfarin after
UFH (or LMWH) treatment is more variably applied variable advice given regarding HRT and more studies
are required to evaluate this risk.and this issue has recently been reviewed in some
detail.12,30 The subject remains contentious and reflects In conclusion, the majority of vascular surgeons in
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